

10/552842

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Applicant: Abbott GmbH & Co. KG

JC20 Rec'd PCT/PTO 11 OCT 2005

Serial No.:

) Group Art Unit:

Filed: October 11, 2005

)

For:

)

Examiner:

)

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
Washington, D.C. 20231


Sir:

Attached Form PTO/SB/08A lists references which may be considered to be material to the above-identified application by the Patent Examiner. Copies of the references are enclosed. Entry into the record is respectfully requested.

Respectfully submitted

By \_\_\_\_\_


Martin L. Katz, Reg. No. 25,011



WOOD, PHILLIPS, KATZ, CLARK & MORTIMER  
Citicorp Center, Suite 3800  
500 West Madison Street  
Chicago, Illinois 60661-2511  
312/876-1800

CERTIFICATE OF MAILING

I hereby certify that this paper is being deposited with the United States Postal Service with sufficient postage at First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on October 11, 2005.



1020 Receipt PTO 11 OCT 2005

Comparable to Form PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<p>Substitute for form 1449A/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p><i>(Use as many sheets as necessary)</i></p>				Application Number	10/552842
				Filing Date	October 11, 2005
				First Named Inventor	Wilfried Braje, et al.
				Group Art Unit	
				Examiner Name	
Sheet	1	of	2	Attorney Docket No.	ABB10043P0013US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		Number Kind Code <sup>2</sup> (if known)			
/E.B./		US- 6,472,392 B1	10/29/2002	Starck, et al.	
		US- 6,090,807	07/18/2000	Hellendahl, et al.	
		US- 5,958,923	09/28/1999	Hellendahl, et al.	
		US- 4,577,020	03/18/1986	Gall	
V		US- 6,342,604 B1	01/29/2002	Hellendahl, et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials <sup>4</sup>	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)			
/E.B./		WO 03/002543 A1	01/09/2003	Abbott Laboratories	
/E.B./		WO 2004/058265 A1	07/15/2004	BIOFOCUS PLC	
Examiner Signature	/Emily Bernhardt/			Date Considered	03/17/2008

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standards ST.16, if possible. <sup>6</sup> Applicant is to place a checkmark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) and application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO				Application Number	10/552842	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	October 11, 2005	
(Use as many sheets as necessary)				First Named Inventor	Wilfried Braje, et al.	
				Group Art Unit		
				Examiner Name		
Sheet		2	of	2	Attorney Docket No.	ABB10043P0017US

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T <sup>2</sup>
		J. C. SCHWARTZ, ET AL. <i>The Dopamine D<sup>3</sup> Receptor as a Target for Antipsychotics</i> pp. 135-144				
		S. M. BROMIDGE, ET AL. <i>5-Chloro-N-(4-methoxy-3piperazin-1-yl)-3-methyl-2-benzothiophenesulfonamide (SB-271046): A Potent, Selective, and Orally Bioavailable 5-HT<sub>6</sub> Receptor Antagonist</i> pp.202-205				
		S. M. BROMIDGE, ET AL. <i>Novel (4-Piperazin-1-ylquinolin-6-yl) Arylsulfonamides with High Affinity and Selectivity for the 5-HT<sub>6</sub> Receptor</i> pp. 2843-2846				
		B. WILLECOMME <i>Recherches Dans La Série De La Piperazine</i> pp. 405-428				
		J. N. JOYCE <i>Dopamine D<sup>3</sup> receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs</i> pp. 232-259				
		P. SOKOLOFF, ET AL. <i>Localization and Function of the D<sup>3</sup>-Dopamine Receptor</i> pp.224-230				
		P. SOKOLOFF, ET AL. <i>Molecular cloning and characterization of a novel dopamine receptor (D<sup>3</sup>) as a target for neuroleptic</i> pp. 146-151				
		M. DOOLEY, ET AL. <i>Pramipexole A Review of its Use in the Management of Early and Advanced Parkinson's Disease</i> pp. 495-513				
Examiner Signature					Date Considered	

\*EXAMINER: Initial if preference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and pay the USPTO to process) and application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450.